*Across clinical studies, the range of A1C reduction from baseline was 0.7% to 1.6% for the 0.75 mg dose and
0.8% to 1.6% for the 1.5 mg dose; the percentage of patients achieving A1C <7% ranged from 37% to 69% for 0.75
mg and 53% to 78% for 1.5 mg.1-5
Therapeutic indications: Trulicity is indicated in adults with type 2 diabetes mellitus to improve
glycaemic control as:
Monotherapy When diet and exercise alone do not provide adequate glycaemic control in patients for whom
the use of metformin is considered inappropriate due to intolerance or contraindications.
Add-on therapyIn combination with other glucose-lowering medicinal products including insulin, when
these, together with diet and exercise, do not provide adequate glycaemic control
Posology:
MonotherapyThe recommended dose is 0.75 mg once weekly.
Add-on therapy The recommended dose is 1.5 mg once weekly.
For potentially vulnerable populations, such as patients ≥ 75 years, 0.75 mg once weekly can be considered
as a starting dose.
When Trulicity is added to existing metformin and/or pioglitazone therapy, the current dose of metformin
and/or pioglitazone can be continued. When it is added to existing therapy of a sulphonylurea or prandial
insulin, a reduction in the dose of sulphonylurea or insulin may be considered to reduce the risk of
hypoglycaemia
Method of Administration: Trulicity is to be injected subcutaneously in the abdomen, thigh or upper arm.
It should not be administered intravenously or intramuscularly. The dose can be administered at any time of day,
with or without meals.
Contraindication: Hypersensitivity to the active substance or to any of the excipients.
Also in patients with a personal or family history of MTC “medullary thyroid carcinoma“ and in patients with
Multiple Endocrine
Neoplasia syndrome type 2 (MEN 2)
.
Undesirable Effects: The most frequently reported adverse reactions in clinical trials were
gastrointestinal, including nausea, vomiting and diarrhoea. In general these reactions were mild or moderate in
severity and transient in nature.
For more information, please refer to the full Summary of Product Characteristics
References
- Trulicity [Summary of Product Characteristics]. Houten, The Netherlands: Eli Lilly and Company; 2014.
- Trulicity Instructions for Use
- Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial [published correction appears in Lancet. 2014;384:1348]. Lancet. 2014;384:1349-1357.
- Umpierrez G, Tofé Povedano S, Pérez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168-2176.
- Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241-2249.
